Physician profile
Aerik A Williams
NPI 1326212986
$298,488.77
in general payments reported to CMS, 2019-2025
41 companies · $80K in 2025
The $80K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $11K · 2021: $25K · 2022: $53K · 2023: $60K · 2024: $66K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $159K · Consulting Fee: $16K · Food and Beverage: $16K · Travel and Lodging: $10K · Honoraria: $6,147 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $158,811.04 |
| Consulting Fee | $15,883.65 |
| Food and Beverage | $15,716.86 |
| Travel and Lodging | $10,275.72 |
| Honoraria | $6,147.00 |
| Education | $113.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $91,411.37 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Abbvie INC. | $75,397.29 | 2021-2025 | Rinvoq |
| Aimmune Therapeutics, INC. | $49,065.16 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $48,299.89 | 2019-2025 | Dupixent |
| Genentech, INC. | $5,642.10 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $5,164.36 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $4,909.89 | 2023-2025 | Ayvakit |
| Amgen INC. | $4,387.01 | 2021-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $3,096.48 | 2021 | |
| Glaxosmithkline, LLC. | $2,509.28 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Biocryst US Sales Co., LLC | $1,519.37 | 2021-2025 | Orladeyo |
| Sanofi US Services INC. | $1,462.97 | 2025 | |
| Pfizer INC. | $968.24 | 2019-2025 | |
| Genzyme Corporation | $934.30 | 2019-2025 | |
| Csl Behring | $606.21 | 2019-2025 | Hizentra, Andembry, Haegarda |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $452.93 | 2021-2025 | Hyqvia, Cuvitru, Eohilia |
| Optinose US, INC. | $420.39 | 2019-2025 | |
| Alk-Abello, INC | $369.90 | 2019-2024 | Odactra, Grastek, Ragwitek |
| Genentech USA, INC. | $202.10 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $187.58 | 2019-2025 | Ruconest |
| Incyte Corporation | $181.77 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $164.28 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $163.52 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $163.46 | 2019-2023 | |
| Ionis Pharmaceuticals, INC. | $113.71 | 2025 | Dawnzera |
| Grifols USA, LLC | $113.19 | 2020-2025 | Xembify |
| Shire North American Group INC | $111.85 | 2019 | |
| Alkermes, INC. | $105.86 | 2022 | |
| Kaleo, INC. | $80.52 | 2022-2024 | Auvi-Q |
| Organon LLC | $55.90 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $43.38 | 2024-2025 | Nemluvio |
| Aytu Biopharma, INC. | $29.14 | 2019-2022 | |
| Octapharma USA, INC. | $23.62 | 2023 | Cutaquig |
| Greer Laboratories, INC. | $22.47 | 2024 | Oralair |
| Adma Biomanufacturing LLC | $19.65 | 2024-2025 | |
| Phadia US INC. | $18.02 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.16 | 2025 | Xhance, Nuzyra |
| Horizon Therapeutics Plc | $14.24 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $13.24 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aerik Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.